{
    "clinical_study": {
        "@rank": "168216", 
        "acronym": "RESTORE", 
        "arm_group": [
            {
                "arm_group_label": "Drug Eluting Stent", 
                "arm_group_type": "Active Comparator", 
                "description": "Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition)"
            }, 
            {
                "arm_group_label": "paclitaxel eluting balloon", 
                "arm_group_type": "Experimental", 
                "description": "paclitaxel eluting balloon (SeQuent Please)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to establish the safety and effectiveness of paclitaxel eluting\n      balloon (SeQuent Please) compared to coronary stenting with the Everolimus-eluting balloon\n      expandable stent (Xience Prime or Xience Xpedition) in the treatment of drug eluting stent\n      restenosis."
        }, 
        "brief_title": "Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Restenosis", 
        "condition_browse": {
            "mesh_term": "Coronary Restenosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient must be more than or equal to 20 years of age\n\n          -  Restenosis after drug-eluting stents (>50% by visual estimate)\n\n          -  Any Lesion length including focal in stent restenosis or diffuse in stent restenosis\n\n          -  The patient or guardian agrees to the study protocol and the schedule of clinical and\n             angiographic follow-up, and provides informed, written consent, as approved by the\n             appropriate Institutional Review Board/Ethical Committee of the respective clinical\n             site.\n\n        Exclusion Criteria:\n\n          -  The patient has a known hypersensitivity or contraindication to any of the following\n             medications:\n\n               -  Heparin\n\n               -  Aspirin\n\n               -  Both Clopidogrel and TIclopidine\n\n               -  Sirolimus eluting stent\n\n               -  Stainless steel and/or\n\n               -  Contrast media (patients with documented sensitivity to contrast which can be\n                  effectively pre-medicated with steroids and diphenhydramine [e.g. rash] may be\n                  enrolled. Patients with true anaphylaxis to prior contrast media, however,\n                  should not be enrolled)\n\n          -  Systemic (intravenous) Everolimus use within 12 months.\n\n          -  Female of childbearing potential, unless a recent pregnancy test is negative, who\n             possibly plan to become pregnant any time after enrollment into this study\n\n          -  Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may\n             result in protocol non-compliance (per site investigator's medical judgment)\n\n          -  Patients who are actively participating in another drug or device investigational\n             study, which have not completed the primary endpoint follow-up period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "260", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01967199", 
            "org_study_id": "AMCCV2013-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Drug Eluting Stent", 
                "description": "Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition)", 
                "intervention_name": "Everolimus-eluting balloon expandable stent", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "paclitaxel eluting balloon", 
                "description": "paclitaxel eluting balloon (SeQuent Please)", 
                "intervention_name": "paclitaxel eluting balloon", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "drug-eluting stent", 
            "drug-coated Balloon", 
            "recurrent In-Stent restenosis"
        ], 
        "lastchanged_date": "February 3, 2014", 
        "location": {
            "contact": {
                "email": "sjpark@amc.seoul.kr", 
                "last_name": "Seung-jung Park, MD, PhD", 
                "phone": "82-2-3010-4812"
            }, 
            "contact_backup": {
                "email": "cvcrc10@amc.seoul.kr", 
                "last_name": "Jeong-youn Bae", 
                "phone": "82-2-3010-7259"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Songpa-gu", 
                    "zip": "138-736"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": {
                "last_name": "Seung-jung Park, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Treatment of Drug-Eluting Stent REstenosis Using Drug-Eluting STents vs. Drug-COated Balloon for Preventing REcurrent In-Stent Restenosis", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Late luminal loss at 9 months angiographic follow-up.", 
            "measure": "Late luminal loss", 
            "safety_issue": "No", 
            "time_frame": "9months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01967199"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "Seung-Jung Park", 
            "investigator_title": "M.D, Ph.D.", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Death", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Myocardial infarction", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Target lesion revascularization", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Target vessel revascularization", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "In-segment or in-stent restenosis at 9 month angiographic follow-up", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "defined as achievement of a final diameter stenosis of <30% by QCA(Quantitative Coronary Angiography) using any percutaneous method, without the occurrence of death, Q wave Myocardial Infarction, or repeat revascularization of the target lesion during the hospital stay.\nparticipants will be followed for the duration of hospital stay, an expected average of 3days.", 
                "measure": "Procedural success", 
                "safety_issue": "Yes", 
                "time_frame": "3day"
            }
        ], 
        "source": "Asan Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seung-Jung Park", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}